Malignancy Rates

Malignancy rates similar to MTX at 1 year, and consistent over 10 years¹*

Malignancy rates (events/patient-year) from the ERA trial in the open-label extension^†

ERA SIR 0.99 (95% CI: 0.67-1.42)

View Study Design

Understanding the Data^1,2:

The malignancy rates in the COMET^‡ trial and Psoriatic Arthritis pivotal trial were consistent with the rates shown here
The ERA SIR^§ was 0.99 (95% CI: 0.67-1.42), indicating that malignancy types and rates in the ERA trial were consistent with the general US population
- Analysis of overall malignancy rates in ENBREL studies has demonstrated types and rates similar to those expected in the SEER database and suggests no increase over time
The SI and Malignancy rates in the LRA, COMET, TEMPO, PRESERVE, and PsA trials were consistent with the rates shown
The most common malignancies included: Lymphoma, prostate carcinoma, lung carcinoma, and breast carcinoma
In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown.
Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Footnotes¹:

* Data are from clinical trials and include all Surveillance, Epidemiology, and End Results (SEER)-defined cancers (excluding nonmelanoma skin cancers, in situ carcinomas except bladder, and recurrent cancers) and comparisons are based on age and sex-matched cohorts.
† Observed on study or within 30 days after the last ENBREL dose. The population for each year reflects all adult patients at the time of analysis who received at least 1 dose of study drug.
‡ In Year 1 of the COMET trial, safety was analyzed using the ITT population (N=542), which was defined as all enrolled subjects in the trial who received at least 1 dose of the study drug. In Year 2, the ITT population (N=411) was defined as all subjects who received at least 1 dose of study drug during Period 2.
§ SIR=standardized incidence ratio.
Malignancy data excludes NMSC.

Study Design

Expand to View

THE EARLY RA TRIAL AND OPEN-LABEL EXTENSION^1-5:

Multicenter, double-blind, double-dummy, Phase 3 trial
632 MTX-naive patients with early moderately to severely active RA (≤3 years' duration) were randomized to receive twice-weekly ENBREL 25 mg (n=207), twice-weekly ENBREL 10 mg (n=208), or MTX (n=217). The mean duration of disease for these patients was 11 to 12 months
This trial became open-label and unblinded after all patients had completed 1 year of evaluation. Patients continued through 1 year of follow-up on the treatment to which they had been randomized. At the end of Year 2, patients switched to or continued twice-weekly ENBREL 25 mg subcutaneously
Subjects could re-enroll in the continuing open-label portion of the study upon meeting specific predefined re-enrollment inclusion criteria

THE LONGSTANDING RA OPEN-LABEL EXTENSION TRIAL^1,6:

714 adult patients with moderately to severely active RA (mean duration of disease: 12 years) who had a previous inadequate response to 1 or more DMARDs and had received ENBREL either as monotherapy or in combination with MTX in various clinical trials
Use of concomitant corticosteroids and/or NSAIDs was permitted during the study
Most patients received ENBREL 25 mg twice weekly. Because all patients did not enter clinical trials at the same time, length of follow-up varies
All 714 adult patients who received at least 1 dose of ENBREL were evaluated for safety. There was no active control or placebo arm in this open-label extension

Serious and Opportunistic Infection Rates Important Safety Information

Supportive data

Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

ENBREL is the #1 most prescribed biologic by rheumatologists*

See why

*6-month average of IMS monthly NPA prescription data by rheumatologists.

IMS NPA prescription data does not include products administered by infusion.

Simplify the reimbursement process

We can help take the confusion out of insurance verifications and prior authorizations.

Download forms

Prescribing Information Medication Guide

Malignancy Rates